Ado-trastuzumab emtansine (also called T-DM1 or trade name Kadcyla®) is an ADC that is used for the treatment of advanced breast cancers that are strongly positive for HER2 [13,14,15]. This evidence concerns the gene ERBB2 and breast carcinoma.